Biochemical and Biological Properties of a Recombinant Tissue-Type Plasminogen Activator Derived from the Rat JMI-229 Cell Line

Summary

Recombinant tissue-type plasminogen activator (rt-PA), produced by expression of the genomic t-PA DNA from the JMI-229 cell line, which is of rat origin, in the host cell line, was purified to homogeneity. JMI-229 rt-PA was obtained essentially as a single chain molecule which was quantitatively converted to a two-chain moiety by treatment with plasmin. The plasminogen activating potential of single chain JMI-229 rt-PA was 5-fold lower than that of commercially available human rt-PA (Actilyse®) in the absence of fibrin, but comparable in the presence of fibrin; it showed a concentration-dependent binding to fibrin, with a significantly more pronounced binding than Actilyse® at low fibrin concentration (85 ± 8% versus 20 ± 7% at 0.025 mg/ml fibrin; p = 0.004). In human plasma in the absence of fibrin, the concentrations of both single chain and two-chain JMI-229 rt-PA required to induce 50% fibrinogen degradation in 2 h, were about 15-fold higher than those of Actilyse®. Both single chain and two-chain forms of JMI-229 rt-PA and of Actilyse® induced a similar time- and concentration-dependent lysis of a ¹²⁵I-fibrin-labeled plasma clot immersed in human plasma, in the absence of significant systemic fibrinolytic activation. Equally effective concentrations (causing 50% clot lysis in 2 h) were 0.11 or 0.10 pg/ml for single chain or two-chain JMI-229 rt-PA, as compared to 0.11 or 0.15 pg/ml for single chain or two-chain Actilyse®. Continuous infusion over 60 min of single chain JMI-229 rt-PA or Actilyse® in hamsters with a ¹²⁵I-fibrin-labeled pulmonary embolus, revealed a very similar thrombolytic potency (clot lysis versus dose) and specific thrombolytic activity (clot lysis versus steady state plasma antigen level of t-PA). The initial plasma half-life following intravenous bolus injection of 0.10 mg/kg in hamsters was equally short for JMI-229 rt-PA or Actilyse® (1.2 or 1.4 min respectively).

It is concluded that JMI-229 rt-PA has a higher fibrin-affinity and a higher fibrin-specificity in human plasma in the absence of fibrin than Actilyse®, but a comparable thrombolytic potency in a hamster pulmonary embolism model.

• References

• 1 Collen D, Lijnen HR, Todd PA, Goa KL. Tissue-type plasminogen activator. A review of its pharmacology and therapeutic use as a thrombolytic agent. Drugs 1989; 38: 346-388
• 2 Pennica D, Holmes WE, Kohr WJ, Harkins RN, Vehar GA, Ward CA, Bennett WF, Yelverton E, Seeburg PH, Heyneker HL, Goeddel DV, Collen D. Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli . Nature 1983; 301: 214-221
• 3 Joernvall H, Pohl G, Bergsdorf N, Wallen P. Differential proteolysis and evidence for a residue exchange in tissue plasminogen activator suggest possible association between two types of protein microheterogeneity. FEBS Lett 1983; 156: 47-50
• 4 Hoylaerts M, Rijken DC, Lijnen HR, Collen D. Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. J Biol Chem 1982; 257: 2912-2919
• 5 Collen D. Coronary thrombolysis: streptokinase or recombinant tissue-type plasminogen activator?. Ann Intern Med 1990; 112: 529-538
• 6 Krause J. Catabolism of tissue-type plasminogen activator (t-PA), its variants, mutants and hybrids. Fibrinolysis 1988; 2: 133-142
• 7 Lijnen HR, Collen D. Tissue-type plasminogen activator: mutants, variants and adjunctive treatment. Biotechn Therap 1990; 1: 273-304
• 8 Collen D, Lijnen HR, Vanlinthout I, Kieckens L, Nelles L, Stassen JM. Thrombolytic and pharmacokinetic properties of human tissue-type plasminogen activator variants, obtained by deletion and/or duplication of structural/functional domains in a hamster pulmonary embolism model. Thromb Haemostas 1991; 65: 174-180
• 9 Collen D, Stassen JM, Larsen G. Pharmacokinetics and thrombolytic properties of deletion mutants of human tissue-type plasminogen activator in rabbits. Blood 1988; 71: 216-219
• 10 Wu Z, Van de Werf F, Stassen T, Mattsson C, Pohl G, Collen D. Pharmacokinetics and coronary thrombolytic properties of two human tissue-type plasminogen activator variants lacking the finger-like, growth factor-like and first kringle domains (amino acids 6-173), in a canine model. J Cardiovasc Pharmacol 1990; 16: 197-203
• 11 Gardell SJ, Duong LT, Diehl RE, York JD, Hare TR, Register RB, Jacobs JW, Dixon RAF, Friedman PA. Isolation, characterization, and cDNA cloning of a vampire bat salivary plasminogen activator. J Biol Chem 1989; 264: 17947-17952
• 12 Shebuski RJ, Fujita T, Ramjit DR, Stabilito IJ, Cuca GC, Gould SL, Wang S, Tung JS, Mark GE, Ellis RW, Silberklang M, Gardell SJ. Thrombolytic efficacy of I.V. bolus vampire bat (bPA) in a rabbit model of femoral arterial thrombosis: comparison to tissue-type plasminogen activator (tPA). Fibrinolysis 1990; 4 Suppl (03) 97 (Abstract 248)
• 13 Ny T, Leonardsson G, Hsueh AJ. Cloning and characterization of a cDNA for rat tissue-type plasminogen activator. DNA 1988; 7: 671-677
• 14 Atkinson A, Doyle A, Kearns MJ, Melling J, North JR, Riley P, Scarven M, Small IS, Sutton PM, Griffiths JB, Electricwala A. UK Patent Application 9000629.7
• 15 Lijnen HR, Van Hoef B, De Cock F, Collen D. Effect of fibrin-like stimulators on the activation of plasminogen by tissue-type plasminogen activator (t-PA). Studies with active site mutagenized plasminogen and plasmin resistant t-PA. Thromb Haemostas 1990; 64: 61-68
• 16 Zamarron C, Lijnen HR, Collen D. Kinetics of the activation of plasminogen by natural and recombinant tissue-type plasminogen activator. J Biol Chem 1984; 259: 2080-2083
• 17 Alessi MC, Declerck PJ, De Mol M, Nelles L, Collen D. Purification and characterization of natural and recombinant human plasminogen activator inhibitor-1 (PAI-1). Eur J Biochem 1988; 175: 531-540
• 18 Holvoet P, Cleemput H, Collen D. Assay of human tissue-type plasminogen activator (t-PA) with an enzyme-linked immunosorbent assay (ELISA) based on three murine monoclonal antibodies to t-PA. Thromb Haemostas 1985; 54: 684-687
• 19 Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-254
• 20 Astrup T, Muellertz S. Fibrin plate method for estimating fibrinolytic activity. Arch Biochem Biophys 1952; 40: 346-351
• 21 Gaffney PJ, Curtis AD. A collaborative study to establish the 2nd international standard for tissue plasminogen activator (t-PA). Thromb Haemostas 1987; 58: 1085-1087
• 22 Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sei USA 1979; 76: 4350-4354
• 23 Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol 1957; 17: 237-246
• 24 Friberger P, Knos M. Plasminogen determination in human plasma. In: Chromogenic Peptide Substrates. Churchill Livingstone; Edinburgh: 1979. pp 128-140
• 25 Edy J, Collen D, Verstraete M. Quantitation of the plasma protease inhibitor antiplasmin with the chromogenic substrate S-2251. In: Progress in Chemical Fibrinolysis and Thrombolysis, Vol. 3. Raven Press; New York: 1978. pp 315-322
• 26 Chmielewska J, Ranby M, Wiman B. Kinetics of the inhibition of plasminogen activators by the plasminogen-activator inhibitor. Evidence for “second site” interactions. Biochem J 1988; 251: 327-332
• 27 Erlanger BF, Kokowsky N, Cohen W. The preparation and properties of two new chromogenic substrates of trypsin. Arch Biochem Biophys 1962; 95: 271-278
• 28 Zamarron C, Lijnen HR, van Hoef B, Collen D. Biological and thrombolytic properties of proenzyme and active forms of human urokinase. I. Fibrinolytic and fibrinogenolytic properties in human plasma in vitro of urokinases obtained from human urine or by recombinant DNA technology. Thromb Haemostas 1984; 52: 19-23
• 29 Stassen JM, Vanlinthout I, Lijnen HR, Collen D. A hamster pulmonary embolism model for the evaluation of the thrombolytic and pharmacokinetic properties of thrombolytic agents. Fibrinolysis 1990; 4: 15-21
• 30 Gibaldi M, Perrier D. Pharmacokinetics. Marcel Dekker; New York: 1983. pp 45-111
• 31 Vehar GA, Spellman MW, Keyt BA, Ferguson CK, Keck RG, Chloupek RC, Harris R, Bennett WF, Builder SE, Hancock WS. Characterization studies of human tissue-type plasminogen activator produced by recombinant DNA technology. Cold Spring Harbor Symposia on Quantitative Biology 1986; LI: 551-562